The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Synthetic organisms, mirror-reversed on the molecular level from natural life, could be a possibility within decades. They could interact with humans and the environment in unpredictable, potentially dangerous ways.
The therapy increases the amount of blood the heart can pump and dramatically improves survival, in what a paper describing the results calls “an unprecedented recovery of cardiac function.”
CommonSpirit Health and 㽶Ƶ of Utah Health are pleased to announce a strategic clinical alliance that will give patients increased access to high-performing, world-class medical care close to home.
Dr. Garrido-Laguna will provide a Phase I clinical trial design overview. The Project Optimus FDA initiative will be explained and future directions for Phase I research will be addressed.
(External Link)
In the News
Sep 26, 2024
Where do creative thoughts come from? How can we harness our stream of consciousness and spontaneity to express ourselves? How are mind-wandering, meditation, and the arts good for our creativity...
(External Link)
In the News
Aug 02, 2024
In 2018, Ruth Hill got out of bed one morning and felt her spine literally break. The 53-year-old collapsed to the floor. “I knew something catastrophic had happened,” Ruth says.
(External Link)
In the News
Aug 01, 2024
In this episode, Holli and Brett discuss the integration of the Family Frailty Score as an assessment tool for patients undergoing advanced heart failure therapies. Various key considerations surrounding the...
(External Link)
In the News
Jun 17, 2024
We all know it's important to wear sunscreen before stepping outside in the sun, but how many of us do it consistently? Let's Get Moving Host Maria Shilaos speaks with...
㽶Ƶ of Utah announces an expansion of the Learn + Earn (L+E) program, made possible with support of Cambia Health Foundation. The initiative is focusing on addressing the critical shortage...
The American College of Surgeons (ACS) has named Thomas K. Varghese Jr., MD, as the next Editor-In-Chief of the Journal of the American College of Surgeons.
㽶Ƶ of Utah Hospital earned the prestigious international Baby-Friendly designation for the fourth time, and is the only facility in Utah to hold this important accreditation.
The Division of Hematology at the 㽶Ƶ of Utah's Department of Internal Medicine is pleased to announce that Anna Beaudin, PhD, has been named the inaugural holder of the John...
Valerie Vaughn, MD, MS, SFHM, FACP, Associate Professor in the Division of General Internal Medicine and Director of Clinical Research for the Department of Internal Medicine, has been selected as...
